NCT07564050

Brief Summary

The goal of this clinical trial is to evaluate the performance and physiological effects of different preoxygenation devices in healthy adult and pediatric volunteers (children aged 5-12 years). The study aims to determine how these devices influence oxygen delivery, airway pressure, and cardiopulmonary physiology during preoxygenation. The main questions it aims to answer are:

  • What fraction of inspired oxygen (FiO₂) is delivered by non-rebreather masks (NRM) compared to bag-valve masks (BVM) with and without positive end-expiratory pressure (PEEP)?
  • How do these devices differ in terms of generated PEEP, inspiratory effort, and their effects on lung ventilation and cardiac function? Researchers will compare NRM, BVM without PEEP, and BVM with PEEP (each with or without supplemental oxygen via nasal cannula) to evaluate differences in oxygenation and physiological effects. Participants will:
  • Complete multiple 3-minute preoxygenation sessions using each device in randomized order
  • Breathe spontaneously through each device, with or without additional oxygen via nasal cannula
  • Undergo non-invasive monitoring of oxygen concentration (FiO₂), respiratory parameters, airway pressures, and ultrasound assessment of the lungs, diaphragm, and heart
  • Perform a brief breath-holding maneuver to assess airway pressure generation

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
1mo left

Started May 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 26, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 4, 2026

Completed
19 days until next milestone

Study Start

First participant enrolled

May 23, 2026

Expected
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2026

Last Updated

May 4, 2026

Status Verified

April 1, 2026

Enrollment Period

1 month

First QC Date

April 26, 2026

Last Update Submit

April 26, 2026

Conditions

Keywords

PreoxygenationBag-valve mask (BVM)Non-rebreather mask (NRM)Positive end-expiratory pressure (PEEP)Fraction of inspired oxygen (FiO₂)Respiratory physiology

Outcome Measures

Primary Outcomes (1)

  • Difference in fraction of inspired oxygen (FiO₂) between preoxygenation devices

    Fraction of inspired oxygen (FiO₂) delivered during preoxygenation will be continuously measured at the airway opening using a gas analyzer. FiO₂ values will be recorded breath-by-breath during each 3-minute preoxygenation session under all study conditions. The primary outcome is the difference in mean FiO₂ achieved between the different preoxygenation devices (non-rebreather mask, bag-valve mask without PEEP, and bag-valve mask with PEEP), with and without supplemental oxygen via nasal cannula.

    During each 3-minute preoxygenation session

Secondary Outcomes (5)

  • Positive end-expiratory pressure (PEEP) generated during preoxygenation

    During each 3-minute preoxygenation session

  • Inspiratory effort required to open the BVM valve

    During each 3-minute preoxygenation session

  • Cardiac function and hemodynamic changes

    Baseline and at the end of each 3-minute preoxygenation session

  • Ventilation of dependent lung regions

    During each 3-minute preoxygenation session

  • Correlation between FiO₂ and tidal volume

    During each 3-minute preoxygenation session

Other Outcomes (1)

  • Airway pressure during breath-holding maneuver

    Immediately following the preoxygenation session with bag-valve mask (with or without PEEP)

Study Arms (7)

Nasal Cannula (NC)

EXPERIMENTAL

Preoxygenation over 3 minutes with a nasal cannula (NC) with supplemental oxygen delivered at 15 L/min, during spontaneous breathing.

Device: Nasal cannula (NC)

Non-rebreather facemask (NRM)

EXPERIMENTAL

Preoxygenation over 3 minutes with a Non-rebreather facemask (NRM) with supplemental oxygen delivered at 15 L/min, during spontaneous breathing.

Device: Non-rebreather mask (NRM)

Non-rebreather facemask (NRM) plus Nasal Cannula (NC)

EXPERIMENTAL

Preoxygenation for 3 minutes using a non-rebreather mask (NRM) combined with a nasal cannula delivering supplemental oxygen at 15 L/min for each device, during spontaneous breathing.

Device: Non-rebreather mask (NRM) plus Nasal cannula (NC)

Bag valve mask (BVM)

EXPERIMENTAL

Preoxygenation for 3 minutes using a bag-valve-mask (BVM) with supplemental oxygen delivered at 15 L/min, during spontaneous breathing.

Device: Bag-valve mask (BVM) without PEEP

Bag valve mask (BVM) plus Nasal cannula (NC)

EXPERIMENTAL

Preoxygenation for 3 minutes using a bag -valve-mask (BVM) combined with a nasal cannula delivering supplemental oxygen at 15 L/min for each device, during spontaneous breathing.

Device: Bag-valve mask (BVM) without PEEP + nasal cannula (NC)

Bag valve mask (BVM) plus PEEP

EXPERIMENTAL

Preoxygenation for 3 minutes using a bag-valve mask (BVM) with positive end-expiratory pressure (PEEP) set at 10 cmH₂O and supplemental oxygen delivered at 15 L/min, during spontaneous breathing.

Device: Bag-valve mask (BVM) with PEEP

Bag valve mask (BVM) plus PEEP plus Nasal Cannula (NC)

EXPERIMENTAL

Preoxygenation for 3 minutes using a bag-valve mask (BVM) with positive end-expiratory pressure (PEEP) set at 10 cmH₂O, combined with a nasal cannula delivering supplemental oxygen at 15 L/min for each device, during spontaneous breathing.

Device: Bag-valve mask (BVM) with PEEP + nasal cannula (NC)

Interventions

Preoxygenation performed using a nasal cannula delivering supplemental oxygen at a flow rate of 15 L/min, without the use of an additional mask or ventilation device, during spontaneous breathing.

Nasal Cannula (NC)

Preoxygenation performed using a non-rebreather mask with reservoir, delivering oxygen at a flow rate of 15 L/min. The mask is fitted to ensure an optimal seal, and participants breathe spontaneously without assisted ventilation.

Non-rebreather facemask (NRM)

Preoxygenation performed using a non-rebreather mask with reservoir, delivering oxygen at a flow rate of 15 L/min, combined with a nasal cannula delivering supplemental oxygen at 15 L/min. The mask is fitted to ensure an optimal seal, and participants breathe spontaneously without assisted ventilation.

Non-rebreather facemask (NRM) plus Nasal Cannula (NC)

Preoxygenation performed using a bag-valve mask without a PEEP valve, delivering oxygen at a flow rate of 15 L/min. The mask is held with a two-handed technique to ensure an airtight seal, without providing assisted ventilation, allowing spontaneous breathing.

Bag valve mask (BVM)

Preoxygenation performed using a bag-valve mask without a PEEP valve, delivering oxygen at a flow rate of 15 L/min, combined with a nasal cannula delivering supplemental oxygen at 15 L/min. The mask is held with a two-handed technique to ensure an airtight seal, without providing assisted ventilation, allowing spontaneous breathing.

Bag valve mask (BVM) plus Nasal cannula (NC)

Preoxygenation performed using a bag-valve mask equipped with a PEEP valve set at 10 cmH₂O, delivering oxygen at a flow rate of 15 L/min. The mask is held with a two-handed technique to ensure an airtight seal, without assisted ventilation, during spontaneous breathing.

Bag valve mask (BVM) plus PEEP

Preoxygenation performed using a bag-valve mask equipped with a PEEP valve set at 10 cmH₂O, delivering oxygen at a flow rate of 15 L/min, combined with a nasal cannula delivering supplemental oxygen at 15 L/min. The mask is held with a two-handed technique to ensure an airtight seal, without assisted ventilation, during spontaneous breathing.

Bag valve mask (BVM) plus PEEP plus Nasal Cannula (NC)

Eligibility Criteria

Age5 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Adults with an American Society of Anesthesiologists (ASA) physical status score ≤ 2
  • Children aged 5 to 12 years with an ASA physical status score ≤ 2
  • Ability (or legal guardian ability) to provide written informed consent

You may not qualify if:

  • Children aged \< 5 years or 13 to 18 years
  • ASA physical status score \> 2
  • Body mass index (BMI) ≥ 30 kg/m²
  • Known airway pathology or anatomical abnormality that could affect mask fit, ventilation, or oxygenation
  • Presence of an active airway infection at the time of the study
  • Pregnancy
  • Refusal or inability to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eurac research, Institute of mountain emergency medicine

Bolzano, BZ, 39100, Italy

RECRUITING

Related Publications (2)

  • Roveri G, Camporesi A, Hofer A, Kahlen S, Breidt F, Rauch S. Preoxygenation With and Without Positive End-Expiratory Pressure in Lung-Healthy Volunteers: A Randomized Clinical Trial. JAMA Netw Open. 2025 May 1;8(5):e2511569. doi: 10.1001/jamanetworkopen.2025.11569.

    PMID: 40392551BACKGROUND
  • Rauch S, Pietsch U, Roveri G. Preoxygenation in prehospital critical care: a survey of HEMS practices in eight European countries. Emerg Med J. 2026 Jan 16:emermed-2025-215335. doi: 10.1136/emermed-2025-215335. Online ahead of print. No abstract available.

    PMID: 41545175BACKGROUND

MeSH Terms

Interventions

Cannula

Intervention Hierarchy (Ancestors)

CathetersEquipment and Supplies

Study Officials

  • Simon Rauch

    Eurac research, Institute of mountain emergency medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Giulia Roveri, MD

CONTACT

Simon Rauch, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

April 26, 2026

First Posted

May 4, 2026

Study Start (Estimated)

May 23, 2026

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

June 30, 2026

Last Updated

May 4, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations